Biopharma
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Alligator Bioscience Slashes 70% of Workforce Due to Financial Strains
Alligator Bioscience, staff cuts, capital constraints, biopharma industry, financial challenges
Navigating JPM Week 2024: Insights and Opportunities in Biopharma
JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends
Empowering Women in Life Sciences: 2024’s Trailblazers in Biopharma R&D
Women in Life Sciences, Biopharma R&D, 2024’s Fiercest Women, Gender Balance, Innovation in Healthcare
Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry
AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements
Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office
Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction
RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry
RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.
Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform
Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.
Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration
RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy